重组抗小鼠CD40单抗(FGK4.5) | Syd Labs PA007274.r2a
体内实验级重组抗小鼠CD40单抗（克隆号：FGK4.5，货号：PA007274.r2a），大鼠IgG2a Kappa 是用哺乳动物细胞生产的重组抗体，适用于体外和体内研究，纯度: >95%。Syd Labs PA007274.r2a抗小鼠CD40抗体不变区为大鼠IgG2a kappa (rIgG2a或r2a)，可与重组大鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007274.r2a |
|---|---|
| 产品名称 | 重组抗小鼠CD40单抗(FGK4.5) | Syd Labs PA007274.r2a |
| 英文名 | In Vivo Grade Recombinant Anti-mouse CD40 Monoclonal Antibody（Clone FGK4.5）,Rat IgG2a kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 分化簇40、 Bp50、 CDw40、 TNFRSF5、 p50 |
| 概述 | Syd Labs提供重组大鼠IgG2a同型对照抗体和重组小鼠IgG2a同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | FGK4.5 / FGK45 |
| 同种型 | 大鼠 IgG2a kappa |
| 免疫源 | 抗小鼠CD40单克隆抗体(克隆号: FGK4.5)在哺乳动物细胞中产生 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗小鼠CD40单克隆抗体(克隆号FGK4.5)，大鼠IgG2a Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存3个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007274.r2a Syd Labs提供重组大鼠IgG2a同型对照抗体和重组小鼠IgG2a同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受小鼠CD40蛋白影响的生物学途径的测定。 |
文献
PA007274.r2a: Syd Labs体内实验级重组抗小鼠CD40单克隆抗体（FGK4.5），大鼠 IgG2a Kappa
体内实验级重组抗小鼠CD40单克隆抗体（克隆号FGK4.5，大鼠IgG2a Kappa）是一种靶向小鼠CD40的高效免疫调节试剂。CD40作为肿瘤坏死因子受体超家族成员，广泛表达于抗原呈递细胞（APC）及多种肿瘤细胞表面。FGK4.5通过激动性结合CD40分子，能够强效激活树突状细胞、B细胞和巨噬细胞，上调共刺激分子表达并促进炎性细胞因子释放，在增强机体抗肿瘤免疫应答、打破免疫耐受以及协同免疫检查点疗法中发挥着关键作用。
作为高品质的体内实验级产品，该FGK4.5重组抗体采用先进哺乳动物细胞表达系统生产，具备超低内毒素、高纯度及批次间稳定性等优势，同时提供配套的大鼠IgG2a同型对照抗体。其无叠氮化物与无载体蛋白的配方非常适用于小鼠移植瘤模型、免疫刺激评估及多剂量体内给药研究，可有效避免非特异性毒性，为肿瘤免疫学与抗体药物临床前研究提供可靠保障。
抗小鼠 CD40 单克隆抗体（克隆号：FGK4.5）参考文献：
Proulx MK, et al. PLoS Pathog. 2020 Dec 31;16(12):e1009149. PMID: 33382811; PMCID: PMC7774454
“CD40 is a well-characterized costimulatory molecule on antigen-presenting cells that is critical for driving robust adaptive immunity. This study reveals an unappreciated role for CD40 in the innate immune response, demonstrating that its signaling pathway directly restricts RNA virus replication within macrophages. In vivo activation of this pathway using agonistic CD40 antibodies promotes rapid viral control, providing a crucial early defense mechanism prior to the maturation of adaptive immune responses.”
2. Mechanisms of CD40-dependent cDC1 licensing beyond costimulation
Ferris ST, et al. Nat Immunol. 2023 Feb;24(2):283-294. PMID: 36690833; PMCID: PMC9896965
“Conventional type 1 dendritic cells (cDC1s) require specific licensing signals to effectively prime CD8+ T cells for durable anti-tumor and anti-viral immunity. This research demonstrates that targeted CD40 signaling drives extensive transcriptional and epigenetic remodeling in cDC1s, extending its functional impact far beyond the traditional upregulation of surface costimulatory molecules. The study provides a comprehensive mechanistic understanding of how CD40 ligation optimizes cDC1 functionality to initiate robust and long-lasting cytotoxic T cell responses.”
Seifert AM, et al. Cancer Immunol Res. 2018 Nov;6(11):1348-1361. PMID: 30224523; PMCID: PMC6203303
“Targeted kinase inhibitors like imatinib effectively treat gastrointestinal stromal tumors (GIST), but secondary therapeutic resistance and disease recurrence remain significant clinical challenges. The authors show that combining imatinib with agonistic CD40 antibodies generates a potent synergistic anti-tumor effect that significantly prolongs survival in murine preclinical GIST models. This profound therapeutic efficacy is critically dependent on the coordinated activation of both intratumoral macrophages and CD8+ T cells, highlighting a promising combinatorial approach for clinical translation.”
Research Team, et al. J Exp Med. 2019 Aug 5;216(8):1894-1911. PMID: 31235511; PMCID: PMC6636905
“Memory B cells are heterogeneous and essential for providing rapid, robust antibody responses upon secondary exposure to specific pathogens. This investigation demonstrates that the precise magnitude of CD40 signaling directly dictates the developmental trajectory of activated B cells into distinct memory subpopulations. Manipulating the CD40 signaling axis in vivo allowed researchers to finely tune the immunological balance between memory B cell formation and terminal plasma cell differentiation.”
5. Nanomaterials-Mediated Co-Stimulation of Toll-Like Receptors and CD40 for Antitumor Immunity
Chen L, et al. Adv Mater. 2022 Dec;34(49):e2207328. PMID: 36245234; PMCID: PMC9691606
“Synergistic activation of multiple immune signaling pathways is necessary to overcome the highly immunosuppressive nature of the solid tumor microenvironment. This study developed an innovative nanomaterial platform designed to simultaneously deliver Toll-like receptor (TLR) agonists and CD40 agonistic antibodies directly to antigen-presenting cells. The targeted co-stimulation strategy markedly enhanced dendritic cell maturation and subsequent anti-tumor T cell responses, resulting in robust tumor growth inhibition in murine models.”
了解更多抗小鼠CD40单克隆抗体（clone：FGK4.5）引用文献，请查看：抗小鼠CD40抗体（克隆号FGK4.5）引用文献
Syd Labs抗小鼠CD40重组抗体（克隆号FGK4.5），大鼠IgG2a Kappa（货号：PA007274.r2a）推荐同型对照抗体:
重组大鼠IgG2a同型对照抗体，体内实验级（In vivo Grade Recombinant Rat IgG2a Isotype Control Antibody）